CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired Noveprim Group for $392.4 million total consideration (2023 step-up to a 90% controlling interest; initial 49% interest acquired in 2022 for $90.0 million plus up to $5.0 million contingent), a transaction completed in November 2023, structured as cash (step acquisition to controlling interest).
Noveprim Group operates in DSA. Mauritius-based supplier of non-human primates (NHPs) for biomedical research; Charles River increased its stake from 49% to a 90% controlling interest.
Expanded Charles River's internal NHP supply for its DSA segment.
Advisory firms were not disclosed for this transaction.